logo BDSP

Base documentaire

  1. Fulltext. Expanded distribution of an investigational drug in parallel with ongoing controlled clinical trials : the didanosine model.

    Article - En anglais


    The purpose of the didanosine Expanded Access Program was to provide a needed antiretroviral agent to individuals who were unable to tolerate other therapy for human immunodeficiency virus infection or in whom such therapy was failing.

    The logistics of establishing this program are described, and the results of on-site auditing that confirmed the validity of the data obtained through this program are presented.

    Mots-clés Pascal : Antiviral, Protocole thérapeutique, Indication, SIDA, Virose, Infection, Chimiothérapie, Traitement, Distribution, Essai clinique, Homme, Programme thérapeutique, Didanosine, Etats Unis, Amérique du Nord, Amérique, Purine nucléoside, Didésoxynucléoside, Immunopathologie, Immunodéficit

    Mots-clés Pascal anglais : Antiviral, Therapeutic protocol, Indication, AIDS, Viral disease, Infection, Chemotherapy, Treatment, Distribution, Clinical trial, Human, Therapeutic schedule, United States, North America, America, Purine nucleoside, Dideoxynucleoside, Immunopathology, Immune deficiency

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 95-0130110

    Code Inist : 002B02S05. Création : 09/06/1995.